Combination Product Industry News & Guidance

Sharing device-related information and wisdom
that will help you succeed

De-risking Biosimilar Development: Article by BD’s Victoria Meyer

Applying cGMPs for Combination Products to Ophthalmic Devices

Suttons Creek is excited to share a new whitepaper from BD that references work by Suttons Creek to improve execution of partner programs in the combination product space.  This qualitative commercial market research study is highlighted in an article written by BD’s Victoria Meyer, Senior Global Strategic Marketing Manager. Her article, first featured on the Drug Development & Delivery website, highlights ways to de-risk the autoinjector launch process, including research-based best practices and considerations around selection of your device partner. Learn more about de-risking and speeding up your combination product launch for a competitive advantage by clicking here.

Want to learn more about how we can support your Commercial Team? Give us a call at 877.661.4SCI or email [email protected].

Victoria Meyer has worked at BD for more than 14 years across several business units in various commercial roles, including sales, sales operations, and regional marketing. She is currently the Senior Global Strategic Marketing Manager responsible for leading 1 mL product platforms across the BD Biologics Portfolio. In this role, she closely partners with Research & Development and other cross functional teams to define, develop, and deliver programs, data sets, and system solutions to pharmaceutical customers to help support combination product development. She earned her MBA from Columbia Business School and her undergraduate degree in Economics from the College of the Holy Cross.